Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 3-4/2021

06.08.2020 | original article

Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration

Long-term retinal changes under anti-vascular endothelial growth factor treatment

verfasst von: MD Christian Ebner, MD Clara Wernigg, MD, PhD, PD Christopher Schütze, MD, PD Birgit Weingessel, MD, MBA Prof. Pia-Veronika Vécsei-Marlovits

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 3-4/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Purpose

The aim of this study was to assess retinal pigment epithelial (RPE) and retinal structural changes in eyes with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) during long-term follow-up and to evaluate morphological markers potentially influencing prognosis.

Methods

A total of 18 eyes of 18 patients with neovascular AMD were examined subsequent to completion of the Avastin Versus Lucentis in Age Related Macular Degeneration (MANTA) study following a mean period of 84 months (range 69–93 months). After receiving a loading dose of 3 intravitreal anti-VEGF injections subsequent to baseline of the MANTA study, patients were treated as needed (pro re nata, PRN). Functional and morphological changes were assessed, the latter using spectral domain optical coherence tomography (SD-OCT).

Results

Retinal/RPE atrophy generally increased significantly during follow-up compared to baseline (fibrosis 28% vs. 89%, p = 0.0001, geographic atrophy, GA 0% vs. 67%, p = 0.0002, RPE porosity 61% vs. 100%, p = 0.009) whereas regenerative alterations tendentially increased until 3 months and then subsequently declined until the last visit (RPE thickening 28% vs. 11%, p = 0.22 and intraretinal hyperreflective foci 89% vs. 78%, p = 0.39).

Conclusion

Atrophic alterations of the retina and RPE are progressive and may partly be induced by anti-VEGF. Morphological findings may aid in the identification of prognostic markers in the progression of neovascular AMD. This could lead to a more targeted education of affected patients.
Literatur
1.
Zurück zum Zitat Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The beaver dam eye study. Ophthalmology. 1992;99(6):933–43. CrossRef Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The beaver dam eye study. Ophthalmology. 1992;99(6):933–43. CrossRef
2.
Zurück zum Zitat Friedman DS, O’Colmain BJ, Munoz B. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–72. CrossRef Friedman DS, O’Colmain BJ, Munoz B. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–72. CrossRef
3.
Zurück zum Zitat Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411. CrossRef Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411. CrossRef
5.
Zurück zum Zitat Busbee BG, Ho AC, Brown DM, HARBOR Study Group.. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–56. CrossRef Busbee BG, Ho AC, Brown DM, HARBOR Study Group.. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–56. CrossRef
6.
Zurück zum Zitat Chang TS, Bressler NM, Fine JT, MARINA Study Group, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460–9. CrossRef Chang TS, Bressler NM, Fine JT, MARINA Study Group, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460–9. CrossRef
7.
Zurück zum Zitat Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83. CrossRef Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83. CrossRef
8.
Zurück zum Zitat CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908. CrossRef CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908. CrossRef
9.
Zurück zum Zitat IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411. CrossRef IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411. CrossRef
10.
Zurück zum Zitat Regatieri CV, Branchini L, Fujimoto JG, et al. Choroidal imaging using spectral-domain optical coherence tomography. Retina. 2012;32:865–76. CrossRef Regatieri CV, Branchini L, Fujimoto JG, et al. Choroidal imaging using spectral-domain optical coherence tomography. Retina. 2012;32:865–76. CrossRef
11.
Zurück zum Zitat Regatieri CV, Branchini L, Duker JS. The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2011;42:S56–66. CrossRef Regatieri CV, Branchini L, Duker JS. The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2011;42:S56–66. CrossRef
12.
Zurück zum Zitat Kumar N, Mrejen S, Fung AT, et al. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. Ophthalmology. 2013;120:334–41. CrossRef Kumar N, Mrejen S, Fung AT, et al. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. Ophthalmology. 2013;120:334–41. CrossRef
13.
Zurück zum Zitat Grunwald JE, Daniel E, Huang J. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–61. CrossRef Grunwald JE, Daniel E, Huang J. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–61. CrossRef
14.
Zurück zum Zitat Schütze C, Wedl M, Baumann B, et al. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:1100–14. CrossRef Schütze C, Wedl M, Baumann B, et al. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:1100–14. CrossRef
15.
Zurück zum Zitat Grunwald JE, Pistilli M, Ying GS, et al. Comparison of age-related macular degeneration treatments trials research group. Incidence and growth of geographic atrophy during 5 years of comparison of Age-related macular degeneration treatments trials. Ophthalmology. 2017;124:97–104. CrossRef Grunwald JE, Pistilli M, Ying GS, et al. Comparison of age-related macular degeneration treatments trials research group. Incidence and growth of geographic atrophy during 5 years of comparison of Age-related macular degeneration treatments trials. Ophthalmology. 2017;124:97–104. CrossRef
16.
Zurück zum Zitat Krebs I, Schmetterer L, Boltz A, MANTA Research Group, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266–71. CrossRef Krebs I, Schmetterer L, Boltz A, MANTA Research Group, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266–71. CrossRef
17.
Zurück zum Zitat Schmitz-Valckenberg S, Fleckenstein M, Göbel AP, et al. Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:1–6. CrossRef Schmitz-Valckenberg S, Fleckenstein M, Göbel AP, et al. Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:1–6. CrossRef
18.
Zurück zum Zitat Bird AC, Phillips RL, Hageman GS. Geographic atrophy: a histopathological assessment. JAMA Ophthalmol. 2014;132:338–45. CrossRef Bird AC, Phillips RL, Hageman GS. Geographic atrophy: a histopathological assessment. JAMA Ophthalmol. 2014;132:338–45. CrossRef
19.
Zurück zum Zitat Jaffe GJ, Martin DF, Toth CA, et al. Comparison of age-related macular degeneration treatments trials research group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120:1860–70. CrossRef Jaffe GJ, Martin DF, Toth CA, et al. Comparison of age-related macular degeneration treatments trials research group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120:1860–70. CrossRef
20.
Zurück zum Zitat Thavikulwat AT, Jacobs-El N, Kim JS, Agrón E, et al. Evolution of geographic atrophy in participants treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2017;1:34–41. CrossRef Thavikulwat AT, Jacobs-El N, Kim JS, Agrón E, et al. Evolution of geographic atrophy in participants treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2017;1:34–41. CrossRef
21.
Zurück zum Zitat Tsuboi S, Pederson JE, Toris CB. Functional recovery of retinal pigment epithelial damage in experimental retinal detachment. Invest Ophthalmol Vis Sci. 1987;28(11):1788–94. PubMed Tsuboi S, Pederson JE, Toris CB. Functional recovery of retinal pigment epithelial damage in experimental retinal detachment. Invest Ophthalmol Vis Sci. 1987;28(11):1788–94. PubMed
22.
Zurück zum Zitat Ho J, Witkin AJ, Liu J, et al. Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2011;118:687–93. CrossRef Ho J, Witkin AJ, Liu J, et al. Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2011;118:687–93. CrossRef
23.
Zurück zum Zitat Lee JY, Folgar FA, Maguire MG. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2014;121:2423–31. CrossRef Lee JY, Folgar FA, Maguire MG. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2014;121:2423–31. CrossRef
24.
Zurück zum Zitat Zweifel SA, Engelbert M, Laud K, et al. Outer retinal tubulation a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127:1596–602. CrossRef Zweifel SA, Engelbert M, Laud K, et al. Outer retinal tubulation a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127:1596–602. CrossRef
25.
Zurück zum Zitat Curcio CA, Zanzottera EC, Ach T, et al. Activated retinal pigment epithelium, an optical coherence tomography biomarker for progression in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58(6):211–26. Curcio CA, Zanzottera EC, Ach T, et al. Activated retinal pigment epithelium, an optical coherence tomography biomarker for progression in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58(6):211–26.
Metadaten
Titel
Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration
Long-term retinal changes under anti-vascular endothelial growth factor treatment
verfasst von
MD Christian Ebner
MD Clara Wernigg
MD, PhD, PD Christopher Schütze
MD, PD Birgit Weingessel
MD, MBA Prof. Pia-Veronika Vécsei-Marlovits
Publikationsdatum
06.08.2020
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 3-4/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01718-6